AM26225PU-N Complement C9 antibody

See related secondary antibodies

Search for all "Complement C9"

0.1 mg / €440.00
Please visit the country specific website of Acris Antibodies or contact your local Distributor to buy this product.

Quick Overview

Mouse anti Equine, Human, Porcine Complement C9 aE11

AM26225PU-N

Product Description for Complement C9

Mouse anti Equine, Human, Porcine Complement C9 aE11.
Presentation: Purified
Product is tested for Immunocytochemistry/Immunofluorescence, Enzyme Immunoassay, Functional assay, Paraffin Sections, Frozen Sections.

Properties for Complement C9

Product Category Primary Antibodies
Target Category
Quantity 0.1 mg
Synonyms Complement 9, Complement component C9
Presentation Purified
Reactivity Eq, Hu, Por
Applications C, E, FN, ICC/IF, P
Clonality Monoclonal
Clone aE11
Host Mouse
Isotype IgG2a
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

Immunogen
Swiss Prot Num:
P02748
GeneID:
735
Isotype control AM03096PU-N
Application Immunohistochemistry on Frozen Sections (Ref.6): 
The typical starting working dilution is 1/50.
Immunohistochemistry on Paraffin Sections (Ref.4): 
The typical starting working dilution is 1/50.
Flow Cytometry (Ref.5): The typical starting working dilution is 1/50.
Functional Studies (Ref.3,5): Inhibits platelet activation by antiphospholipid antibody serum (Ref.5).
Immunoassays (Ref.1,2).
Immunofluorescence (Ref.2,4).
Positive Control: Mucosa from patients with H. Pylori.
Background The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed  the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components.  C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.
Concentration 0.1 mg/ml
General Readings
  1. Mollnes TE, Lea T, Frøland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985 Aug;22(2):197-202. PubMed PMID: 2412280.
  2. Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol. 1985 Aug;22(2):183-95. PubMed PMID: 4035298.
  3. Pettersen HB, Johnson E, Hetland G. Human alveolar macrophages synthesize active complement components C6, C7, and C8 in vitro. Scand J Immunol. 1987 Jun;25(6):567-70. PubMed PMID: 3602933.
  4. Berstad AE, Brandtzaeg P, Stave R, Halstensen TS. Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut. 1997 Feb;40(2):196-203. PubMed PMID: 9071931. (Free PMC Article available)
  5. Stewart, M et al. Antiphospholipid antibody-dependent C5b-9 formation. BJH 1997, 96:451.
  6. Meuwissen, M et al. Colocalisation of intraplauq C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Path 2005, 59:126.
Storage

Store undiluted at 2-8°C. 
Shelf life: one year from despatch.

Format
Purification:
Protein G Chromatography
Buffer System:
PBS
Stabilizers:
0.1% BSA
State:
Liquid 0.2 µm filtered Ig fraction
Purified
Species Reactivity
Species reactivity (tested):
Human, Horse, Swine.
Specificity
Specificity:
This antibody reacts with a C9 neoantigen of the terminal complement complex (TCC).

Accessory Products

Proteins and/or Positive Controls

Proteins for Complement C9 (4 products)

Catalog No. Species Pres. Purity   Source  

Complement C9 (22-559, His-tag)

Complement C9 Human Purified > 80 % by SDS - PAGE E. coli
0.25 mg / €730.00
  Acris Antibodies GmbH

Complement C9 (22-559, His-tag)

Complement C9 Human Purified > 80 % by SDS - PAGE E. coli
50 µg / €300.00
  Acris Antibodies GmbH

Complement C9

Complement C9 Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.

Complement C9

Complement C9 Human 12.5% SDS-PAGE Stained with Coomassie Blue. in vitro transl.
  Abnova Taiwan Corp.

Positive controls for Complement C9 (2 products)

Catalog No. Species Pres. Purity   Source  

C9 Lysate

Western Blot: Complement C9 Lysate [NBL1-08577] - Western Blot experiments. 
Left-Control; Right -Over-expression Lysate for C9
  Novus Biologicals Inc.

C9 overexpression lysate

C9 overexpression lysate
0.1 mg / €295.00
  OriGene Technologies, Inc.
  • LinkedIn